Compounds > ci 953
Page last updated: 2024-11-07

ci 953

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CI 953: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130177
SCHEMBL ID8005154
MeSH IDM0191793

Synonyms (12)

Synonym
n-(2-chloro-6-methylphenyl)-n'-4-pyridinylurea monohydrochloride
ci 953
urea, n-(2-chloro-6-methylphenyl)-n'-4-pyridinyl-, monohydrochloride
4dx3vnx2xv ,
unii-4dx3vnx2xv
124421-10-9
SCHEMBL8005154
n-(2-chloro-6-methylphenyl)-n'-4-pyridinylurea hydrochloride
urea, n-(2-chloro-6-methylphenyl)-n'-4-pyridinyl-, hydrochloride (1:1)
DTXSID30924801
n'-(2-chloro-6-methylphenyl)-n-pyridin-4(1h)-ylidenecarbamimidic acid--hydrogen chloride (1/1)
1-(2-chloro-6-methylphenyl)-3-pyridin-4-ylurea;hydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's3 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenytoin
[no description available]		1.9710imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		1.9710dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
thiazoles
[no description available]		1.97101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
ralitoline
[no description available]		1.9710
batrachotoxinin a 20-alpha-benzoate
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Prolapse
The protrusion of an organ or part of an organ into a natural or artificial orifice.		02.610
Breast Cancer
[description not available]		02.610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.610
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.610
Aura
[description not available]		01.9710
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		01.9710